EMEA-002582-PIP01-19-M01
Key facts
Active substance |
Remibrutinib
|
Therapeutic area |
Dermatology
|
Decision number |
P/0170/2022
|
PIP number |
EMEA-002582-PIP01-19-M01
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of chronic spontaneous urticaria
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|